P atients with severe acute respiratory distress syndrome (ARDS) have a high risk of morbidity and mortality.
METHODS
This study was approved by the Institutional Review Board (University of Pennsylvania Institutional Review Board, email: irb@pobox.upenn.edu, phone: 215-573-2540), and the requirement for written informed consent was waived. We conducted a retrospective study of all consecutive patients with severe ARDS and hemodynamic instability presenting for ECLS from outside hospitals through our mobile ECLS program from January 2, 2015 until December 31, 2015. Hemodynamic instability was defined as requiring vasopressor or inotropic support to maintain a mean arterial pressure greater than 60 mm Hg or a systolic blood pressure greater than 100 mm Hg after normalizing volume status. Patients >18 years of age were considered for ECLS support for ARDS with a Murray Score >3.0 or a pH <7.20. Exclusion criteria included contraindication to heparinzation, ventilator support for >10 days, or a history of severe chronic lung disease.
ECLS was implemented in standard fashion according to our program's protocol. To ensure that we do not place patients on VV ECLS with inadequate cardiac function, our program requires that a cardiac echocardiogram be performed before ECLS is implemented. If the patient has severe ventricular dysfunction associated with severe hemodynamic instability, he/she is considered a candidate for VA ECLS only. In circumstances when patients are too unstable to be transported and the referring facility is unable to obtain a cardiac echocardiogram, we obtain the echocardiogram ourselves by using a portable TEE machine (Phillips CX50 with a TEE probe) that we bring along. This option is possible because our mobile team consists of a cardiac anesthesiologist, cardiovascular surgeon, and a perfusionist.
In our patient cohort, ECLS was initiated as follows: First, both groins and the right neck were draped and prepared in sterile fashion with chloraprep. The right When clinicians consider extracorporeal life support (ECLS) for acute respiratory distress syndrome (ARDS) patients with hemodynamic instability, both veno-arterial (VA) and veno-venous (VV) ECLS are therapeutic possibilities. We analyzed 17 patients with ARDS on inotropic or vasopressor support requiring ECLS for refractory hypoxemia. After implementing VV ECLS, pressor requirements (based on norepinephrine equivalents) were significantly lower in all patients (P = .0001 for overall comparison across time points). None of the 17 patients required conversion from VV ECLS to VA ECLS (95% confidence interval 0%-20.0%). In this sample of 17 patients with substantial baseline vasopressor support and hypoxemic respiratory failure, initiation of VV ECLS was associated with reduced pressor requirements. Such a strategy may help avoid complications of VA ECLS in patients with both respiratory and hemodynamic failure. femoral vein and right internal jugular (IJ) veins were accessed and 0.35 Amplatz wires advanced and positioned within the right atrium using fluoroscopic confirmation. After an IV bolus of 100 U/kg of heparin was administered, a 25F long femoral venous inflow cannula was inserted and a 16F right IJ outflow cannula. In 1 patient, a right internal jugular Avalon catheter was placed instead of bicaval cannulation. After fluoroscopic confirmation of position, the cannulas were connected to a Maquet Cardiohelp portable ECLS machine. ECLS flow was then started and slowly and gradually increased to 4-6 L/min. The gas flow sweep was initially set at 2 L with a fraction of inspired oxygen (Fio 2 ) of 100%. After ECLS had reached steady state, pressors were titrated to maintain mean arterial pressure >60 mm Hg and ultralow stretch ventilator settings were used as tolerated, with positive end expiratory pressure (PEEP) set to 10-12 cm H 2 O and tidal volumes set to 2-4 mL/kg.
Retrospective data collection included patient age at time of ECLS implementation, site of ECLS implementation, hospital length of stay (LOS), intensive care unit (ICU) LOS, duration of ECLS support, and in-hospital mortality. In addition, pH, PEEP or mean airway pressure (for patients on airway pressure release ventilation), and Pao 2 were collected pre (immediately prior) and post (2 hours after) ECMO implementation.
Vasopressor and inotrope requirements were recorded pre-ECLS implementation (T0), 2 hours after implementation (T+2), 6 hours after implementation (T+6), and 24 hours after implementation (T+24). Since most patients were on multiple vasopressor and inotropic support medications, we generated an equivalency score to convert different pressor doses to norepinephrine equivalents. Specifically, we modified the Vasopressin and Septic Shock Trial (VASST) formula to include vasopressin based on recommendations by Patel et al. 7, 8 Vasopressor and inotrope doses were totaled for each patient at each time point and entered into the following formula to calculate norepinephrine equivalents: 
Statistical Analysis
Vasopressor requirements (in norepinephrine equivalents) at each time point were summarized with medians and interquartile ranges. Comparison of vasopressor requirements across time points was done with the Friedman test, followed by pairwise comparisons using the Wilcoxon signed rank test with the Bonferroni correction to account for repeated observations. The alpha level for the overall test (Friedman test) was set at 0.05 and was corrected to 0.008 for the post hoc pairwise comparisons using the Wilcoxon signed rank test. We estimated the correlation between change in vasopressor dose and change in physiologic variables (pH, PEEP, Pao 2 ) using Spearman rank correlation test. Seventeen patients were available at the end of the study period. Assuming that 10% of patients would need conversion to VA ECLS, we calculated that our sample would provide 80% power to exclude an upper confidence limit of 35%.
RESULTS
We identified 35 consecutive patients undergoing VV ECLS for severe ARDS from January 2, 2015 until December 31, 2015. Eighteen patients were excluded from analysis because they did not require vasopressor or iontropic support at the time of ECLS implementation. None of the patients referred with ARDS underwent VA ECLS. ECLS was initiated off-site by a mobile team on 12 of 17 patients, and 5 of 17 patients had ECLS initiated at our institution after transfer from the outside hospital. Single-vein cannulation with a dual-lumen catheter inserted via the right internal jugular vein was performed in 1 patient. All other patients underwent bicaval cannulation. None of the patients sustained cannulationrelated complications.
The pressor requirements at each time point are shown in Table 1 . After VV ECLS implementation, requirements were significantly lower at 6 hours (P = .0003), 24 hours (P = .0003), and overall across all time points (P = .0001) None of the patients required conversion from VV ECLS to VA ECLS (0/17 [0%, 95% confidence interval 0%-20.0%]). ECLS was successfully weaned off in 15 of 17 patients. Hospital mortality was 35.3% (6/17 patients) in this patient cohort.
Five of the patients in our series had ECLS implemented at the bedside with transesophageal echocardiography (TEE) guidance of cannula insertion and position because of perceived risk of cardiovascular collapse with patient movement. In all 5 cases, patient movement before ECLS implementation resulted in severe hypotension or hypoxia. The remaining 12 were transported to the operating room and cannulation was performed with fluoroscopic guidance.
We found in our cohort that an increase in pH 2 hours after ECMO implementation correlated with a reduction in pressor requirements at 6 hours, but not 24 hours (see Table 2 ). Changes in PEEP and Pao 2 associated with ECMO implementation did not correlate with the reduction in pressor requirements. www.anesthesia-analgesia.org
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DISCUSSION
We found that in patients with respiratory failure and hemodynamic instability requiring pressors/inotropes, implementation of VV ECLS decreased the pressor requirement at 6 hours and 24 hours. Two patients still required high-dose pressors 24 hours after initiation of ECLS (23 and 17.5 norepinephrine equivalents), but lower than before insertion. One patient had influenza A pneumonia complicated by methicillin-resistant Staphylococcus aureus pneumonia and bacteremia, and the other had aspiration syndrome. The minimal level of cardiac function required to tolerate VV ECLS remains unknown, but we would be cautious using VV ECLS in patients with severe right or left ventricular dysfunction. Despite the limitations of this retrospective study, the findings provided important information for guiding clinical decision making in patients undergoing ECLS for acute respiratory failure.
In conclusion, we describe the use of VV ECLS in 17 patients with refractory hypoxemia due to ARDS and hemodynamic instability on pressors/inotropes. In nearly all patients, ECLS not only improved oxygenation, but also reduced the need for vasoactive agents. In our cohort, an increase in pH was the only ECMO-related effect that correlated with the reduction in pressor requirements we observed. Further work is needed to identify factors predicting the successful use of VV ECLS in patients with combined respiratory failure and hypotension. E 
